NYSE$CNC

Centene Corp · Q2 2025 earnings

Q2 2025 earnings · · Before market open · Investor relations

Briefing

Centene Corp reported a net loss for the second quarter of 2025 driven by higher medical costs and a reduction in expected Marketplace risk adjustment revenue.

Centene reported total revenues of $48.7 billion for Q2 2025, up 22% year-over-year, primarily from PDP and Marketplace membership growth and Medicaid rate increases. The company posted a GAAP net loss of $253 million and a diluted loss per share of $0.51, with an adjusted diluted loss per share of $0.16. Medical cost trends accelerated due to behavioral health, home health, high-cost drugs, and higher Marketplace morbidity.

  • Total revenues reached $48.7 billion, reflecting 19% PDP membership growth and 33% Marketplace membership growth.
  • HBR rose to 93.0% from 87.6% year-over-year due to elevated medical costs and a significant downward adjustment to 2025 Marketplace risk adjustment revenue.
  • GAAP diluted loss per share was $(0.51) and adjusted diluted loss per share was $(0.16) for the quarter.
  • Operating cash flow for the first half of 2025 was $3.3 billion, supported by improved pharmacy rebate timing.

Headline financials

Total Revenue

$48.7B

Previous: $39.8B+22.4%
EPS (adj)

-$0.16

Previous: $2.16-107.4%
SG&A Expense Ratio

7.1%

Previous: 8.0%-11.3%
Adjusted SG&A Expense Ratio

7.1%

Previous: 8.0%-11.3%
Health Benefits Ratio

93.0%

Previous: 87.6%+6.2%
Capital Expenditures

-$343M

Previous: -$337M-1.8%
Net Income

-$253M

Previous: $1.15B-122.1%
Operating Income

-$458M

Previous: $1.23B-137.3%

Revenue & EPS history

Centene · Revenue · Quarterly

$48.7B

Q2 2025+22.4%vs Q2 2024
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

Centene · $48.7B total across 4 segments · Q2 2025

  • Medicaid
    $28B
  • Commercial
    $10.1B
  • Medicare
    $9.45B
  • Other
    $1.22B

Forward guidance

The company is refiling 2026 Marketplace rates to reflect higher projected morbidity and continues to work with states on Medicaid rate adjustments to match post-redetermination acuity.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports

Historical avg

+0.4%

Avg return

Earnings day

+0.4%

Avg return

5 days after

+1.9%

Avg return

30 days after

54%

37 / 68 earnings

Positive

+13.8%

Q1 2014

Best reaction

-10.4%

Q2 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2025
Q1 2026+0.5%+22.6%+33.9%
Q4 2025-3.7%+1.3%+9.3%
Q3 2025+12.5%+3.9%+18.5%
Q1 2025-6.3%-2.8%-8.4%
Q4 2024-5.4%-9.1%-8.3%
Q3 2024+0.0%+0.3%-2.0%
Q2 2024+9.0%+14.1%+16.5%
Q1 2024-2.4%-4.5%-1.4%
Q4 2023+1.1%+4.4%+7.5%
Q3 2023-3.0%-4.8%+4.7%
Q2 2023-2.7%-3.7%-9.2%
Q1 2023-1.5%+1.9%-6.3%
Q4 2022+2.7%+2.4%-7.7%
Q3 2022+11.9%+13.2%+10.3%
Q2 2022+0.6%+1.1%+4.1%
Q1 2022-4.9%-5.1%-3.5%
Q4 2021+6.4%+3.1%+4.5%
Q3 2021+3.8%+4.8%+11.2%
Q2 2021-4.0%-5.6%-12.5%
Q1 2021-9.9%-6.5%+11.7%
Q4 2020+4.8%+1.6%+6.3%
Q3 2020-7.9%-11.0%-6.3%
Q2 2020-1.4%-3.0%-10.1%
Q1 2020-6.6%-8.3%-5.5%
Q4 2019+5.1%+0.4%-5.0%
Q3 2019+5.7%+5.4%+30.4%
Q2 2019+3.0%+2.4%-12.7%
Q1 2019+4.4%+9.5%+15.3%
Q4 2018-2.9%-3.2%-13.2%
Q3 2018-8.3%-9.9%-5.5%
Q2 2018-3.1%-3.0%+6.0%
Q1 2018-1.2%-0.4%+5.5%
Q4 2017+5.0%+2.3%+0.9%
Q3 2017-7.4%-3.7%-1.1%
Q2 2017-1.0%-1.8%+2.1%
Q1 2017+1.1%+3.3%+4.5%
Q4 2016+7.9%+9.1%+9.3%
Q3 2016+1.4%+0.1%-10.5%
Q2 2016-10.4%-6.3%-10.0%
Q1 2016+4.2%
Q4 2015+2.2%
Q3 2015+5.3%
Q2 2015+0.2%
Q1 2015-9.7%
Q4 2014+5.6%
Q3 2014+9.3%
Q2 2014+5.8%
Q1 2014+13.8%
Q4 2013+4.5%
Q3 2013-4.1%
Q2 2013+5.1%
Q1 2013+4.4%
Q4 2012+6.1%
Q3 2012+0.3%
Q2 2012+6.9%
Q1 2012-6.0%
Q4 2011-2.5%
Q3 2011+12.6%
Q2 2011+3.3%
Q1 2010+10.9%
Q1 2011+2.4%
Q4 2008-6.5%
Q4 2010-6.5%
Q3 2009-6.6%
Q2 2009-6.6%
Q3 2010-6.6%
Q2 2010-5.3%
Q4 2009-5.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro